5-(3-溴苯基)-2H-吡唑-3-胺 | 149246-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(3-溴苯基)-2H-吡唑-3-胺
• 中文别名: 3-(3-溴苯基)-5-氨基吡唑
• 英文名称: 3-(3-bromophenyl)-1H-pyrazol-5-amine
• 英文别名: 5-(3-bromophenyl)-1H-pyrazol-3-amine
• CAS: 149246-81-1
• 化学式: C₉H₈BrN₃
• 分子量: 238.087
• InChiKey: NQFSHBKZGKSELV-UHFFFAOYSA-N

物化性质

• 熔点：
  149-151°C

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933199090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(3-Bromophenyl)-1H-pyrazol-3-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(3-Bromophenyl)-1H-pyrazol-3-amine
CAS number: 149246-81-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrN3
Molecular weight: 238.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(3-溴苯基)-2H-吡唑-3-胺 在 sodium hydroxide 、 diphenyl ether-biphenyl eutectic 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 反应 21.0h， 生成 2-(3-bromophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
  参考文献：
  名称：

  吡唑并[1,5-α]嘧啶酮区域异构体的合成

  摘要：

  这项工作描述了制备吡唑并[1,5-α]嘧啶-7-ones的两种不同途径和两种制备吡唑并[1,5-α] pyrimidin-5-ones的途径。在制备嘧啶-5-酮区域异构体中使用1,3-二甲基尿嘧啶作为亲电子试剂代表了对先前报道结果的修正。另外，鉴定了制备该异构体的新反应并阐明了反应机理。这项工作为实验者提供了互补的合成途径，这些途径提供了嘧啶7-1或嘧啶5-5区域异构体。

  DOI：

  10.1021/jo062120g
• 作为产物：
  描述：

  3-溴苯酰乙腈 在 肼 作用下， 以 甲醇 、 水 为溶剂， 反应 2.25h， 以69%的产率得到5-(3-溴苯基)-2H-吡唑-3-胺
  参考文献：
  名称：

  吡唑并[1,5-α]嘧啶酮区域异构体的合成

  摘要：

  这项工作描述了制备吡唑并[1,5-α]嘧啶-7-ones的两种不同途径和两种制备吡唑并[1,5-α] pyrimidin-5-ones的途径。在制备嘧啶-5-酮区域异构体中使用1,3-二甲基尿嘧啶作为亲电子试剂代表了对先前报道结果的修正。另外，鉴定了制备该异构体的新反应并阐明了反应机理。这项工作为实验者提供了互补的合成途径，这些途径提供了嘧啶7-1或嘧啶5-5区域异构体。

  DOI：

  10.1021/jo062120g

文献信息

• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE RÉPLICATION DU VIRUS D'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014028384A1

  公开（公告）日：2014-02-20

  The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该公开涉及到式(I)的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该公开提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。
• [EN] PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] MACROCYCLES DE PYRAZOLOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015126376A1

  公开（公告）日：2015-08-27

  The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及到I式化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• [EN] PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] MACROCYCLES DE PYRAZOLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015123182A1

  公开（公告）日：2015-08-20

  The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该公开涉及到一种I式化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该公开提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• Synthesis of Purine Analogues: Photocatalyst-Free Visible-Light-Enhanced Annulation Approach to Pyrazolo[1,5-<i>a</i>][1,3,5]triazine-2,4-diamines
  作者：Wei Guo、Zhen Xie、Liuhuan Cai、Gongping Liu、Ling Deng、Weijie Mei、Xiaoying Zou、Yumei Zhong、Xiaoya Zhuo、Lvyin Zheng、Xiaolin Fan

  DOI：10.1021/acs.joc.1c00783

  日期：2021.6.18

  pyrazolo[1,5-a][1,3,5]triazine-2,4-diamines via the formation of electron donor–acceptor (EDA) complexes is reported. The in situ generated pyrazolthiourea intermediates from 1H-pyrazol-3-amines and isothiocyanates undergo formal [4 + 2] annulation with 1,1,3,3-tetramethylguanidines (TMG) to deliver the corresponding products involved in three C–N bond formations in a one-pot protocol. The formation of EDA

  通过形成电子供体 - 受体（EDA）复合物合成吡唑并[1,5- a ][1,3,5]三嗪-2,4-二胺的一种新的无光催化剂可见光增强策略是报道。在原位从1个产生pyrazolthiourea中间体ħ吡唑-3-胺和异硫氰酸酯进行正式[4 + 2]环与1,1,3,3- tetramethylguanidines（TMG）以提供所涉及的三个C-N键的相应的产品在一锅协议中的形成。由吡唑硫脲和 TMG 形成 EDA 复合物通过紫外-可见光谱和1核磁共振实验。此外，这种温和的反应在没有任何外部过渡金属、氧化剂、碱和配体的情况下进行。这种合成嘌呤类似物吡唑并[1,5- a ][1,3,5]三嗪-2,4-二胺的有效方法在药物研发领域提供了潜在的合成应用。
• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。